Votrient (pazopanib) — United Healthcare
Gastrointestinal Stromal Tumor (GIST)
Preferred products
- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)
- Qinlock (ripretinib)
Initial criteria
- Diagnosis of GIST AND disease is unresectable, progressive, or metastatic AND (used as first-line therapy in SDH-deficient GIST OR used after progression on all of the following: Gleevec (imatinib), Sutent (sunitinib), Stivarga (regorafenib), standard dose Qinlock (ripretinib))
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Votrient therapy
Approval duration
12 months